CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
CorMedix Therapeutics (Nasdaq: CRMD) will release its financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026.
Rhea-AI Summary
CorMedix Therapeutics (Nasdaq: CRMD) will release its financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026. The company will also host a corporate update conference call at 8:30 a.m. Eastern Time the same day.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CRMD
In the Jul 29 session, CRMD declined 2.18%, reflecting a moderate negative market reaction. Argus tracked a peak move of +10.7% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Reporting Period
- Second quarter 2026
- Financial results announcement
- Quarter End
- June 30, 2026
- Second quarter 2026
- Report Date
- August 13, 2026
- Before market open
- Conference Call Time
- 8:30am Eastern Time
- Corporate update conference call
Previous Earnings date Reports
-
Scheduled first-quarter results and corporate update for May 14, 2026
-
Scheduled fourth-quarter and full-year results for March 5, 2026
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026, and will host a corporate update conference call at 8:30am Eastern Time.
| Thursday, August 13th @ 8:30am ET | |
| Domestic: | 1-844-676-2922 |
| International: | 1-412-634-6840 |
| Webcast: | Webcast Link |
About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional settings of care in the US and has field based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.